Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are antibodies that target and block immune checkpoints. These biologics were initially approved by the United States Food and Drug Administration (US FDA) in 2011 for the management of melanoma. Since then, the use of ICI therapy has increased, with many new medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshirfar, Majid, Basharat, Noor F., Seitz, Tanner S., Ply, Briana K., Ronquillo, Yasmyne C., Hoopes, Phillip C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572806/
https://www.ncbi.nlm.nih.gov/pubmed/36233514
http://dx.doi.org/10.3390/jcm11195647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572806/
https://www.ncbi.nlm.nih.gov/pubmed/36233514
http://dx.doi.org/10.3390/jcm11195647

Ejemplares similares